“When I reflect on the pancreatic cancer treatment landscape, it has been a bit disappointing, but we have worked through these disappointments, ever since 1997 when we didn’t have a standard of care,” said Kundranda. “That was when we [only] had gemcitabine, a single agent. Read more . . .
Although the pancreatic cancer treatment paradigm has suffered from a period of stagnation, several ongoing research efforts are being made to improve outcomes for patients, according to Madappa Kundranda, MD, PhD, who added that trials like NAPOLI-3 and AVENGER 500 are generating excitement in the space.